Oxtex Limited, a medical device company with its origins from University of Oxford, is developing and commercialising a range of novel devices for soft tissue expansion. These devices have a number of applications in a range of reconstructive and wound closure surgical procedures, restorative dentistry and veterinary surgery.
Incorporated in May 2011, Oxtex has raised significant funds to date and has secured its IP through a number of international patents to protect the know-how and design of its product.
Through collaboration and support of internationally renowned key opinion leaders and veterinary specialist the company has successfully produced and internationally commercialised its veterinary product, Expaniderm, and is in the process of concluding all necessary human regulatory requirements before launching its Qantex product in human patients – expected to be Q2 2019.
The commercial potential of the Oxtex technology has been recognised by the business community; the company received the OBN awards for Best Emerging MedTech in late 2011 and best New Medical Product in 2012 and is a finalist for the WOBA Innovation Award 2019.